H.C. Wainwright analyst Douglas Tsao started Marinus Pharmaceuticals with a Buy rating and $5 price target. Disappointments in focal onset seizures and Fragile X syndrome in 2016 have overshadowed the "robust" Phase 2 data produced in rare orphan epilespies, Tsao tells investors in a research note. Considering peak sales potential in excess of $125M for CDLK5 and $250M for PCDH19, the analyst expects Marinus shares to "appreciate meaningfully" if each of those studies succeeds. He believes CDD and PCDH could each alone be worth up to $2.50 and $8.00 per share, respectively.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Intra-Cellular Therapies... To see the rest of the story go to thefly.com. See Story Here

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Soligenix (SNGX),... To see the rest of the story go to thefly.com. See Story Here